Patent ID: 8809344

Claim:
A method of treating a hepatitis C viral infection in a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition that comprises a therapeutically effective amount of an enantiomer that inhibits hepatitis C viral replication having the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from the group consisting of unsubstituted thienyl-2 and unsubstituted furyl-2; R 2 is selected from the group consisting of —CCl 3 , —CBr 3 , and —CF 3 ; R 3 is —CONHR″3, wherein R″3 is meta-hydroxyalkyl substituted phenyl, or —(X)—R, wherein X is —(CH 2 ) n —, wherein n is 1 or 2, and wherein R is a unsubstituted thienyl-2 and unsubstituted furyl-2 group; R 4 is selected from the group consisting of hydrogen, chloro, bromo, and fluoro; and wherein said compound or salt thereof is an enantiomer with R 1 and R 2 in a syn configuration that inhibits hepatitis C viral replication, thereby treating said hepatitis C viral infection in said subject.